IκB-ζ controls the constitutive NF-κB target gene network and survival of ABC DLBCL

Blood

Volumn 122, Issue 13, 2013, Pages 2242-2250

  Nogai, Hendrik ^a   Wenzel, Sören Sebastian ^a,b   Hailfinger, Stephan ^c   Grau, Michael ^d   Kaergel, Eva ^e   Seitz, Volkhard ^a   Wollert Wulf, Brigitte ^a,e   Pfeifer, Matthias ^a   Wolf, Annette ^a,b   Frick, Mareike ^a   Dietze, Kerstin ^a   Madle, Hannelore ^a   Tzankov, Alexander ^f   Hummel, Michael ^a   Dörken, Bernd ^a,e   Scheidereit, Claus ^e   Janz, Martin ^a,e   Lenz, Peter ^d   Thome, Margot ^c   Lenz, Georg ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

^c UNIVERSITY OF LAUSANNE   (Switzerland)

^d PHILIPPS UNIVERSITY MARBURG   (Germany)

^e MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^f UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B KINASE; I KAPPA B KINASE ALPHA; I KAPPA B KINASE ZETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 6; MESSENGER RNA; MYELOID DIFFERENTIATION FACTOR 88; PROTEIN BCL XL; PROTEIN P100; PROTEIN P105; PROTEIN P50; PROTEIN P52; SMALL INTERFERING RNA; STAT3 PROTEIN; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSCRIPTION FACTOR RELA; TRANSCRIPTION FACTOR RELB; TUBULIN; UNCLASSIFIED DRUG; NFKBIZ PROTEIN, HUMAN; NUCLEAR PROTEIN; TRANSCRIPTOME;

ACTIVATED B CELL LIKE SUBTYPE DIFFUSE LARGE B CELL LYMPHOMA; ARTICLE; COMPARATIVE GENOMIC HYBRIDIZATION; DIFFUSE LARGE B CELL LYMPHOMA; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION PROFILING; GERMINAL CENTER; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RNA INTERFERENCE; GENE REGULATORY NETWORK; GENE SILENCING; GENETIC TRANSDUCTION; GENETICS; HUMAN; LARGE CELL LYMPHOMA; METABOLISM; PHYSIOLOGY; POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

BLOTTING, WESTERN; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE KNOCKDOWN TECHNIQUES; GENE REGULATORY NETWORKS; HUMANS; IMMUNOPRECIPITATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; NF-KAPPA B; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TRANSCRIPTOME; TRANSDUCTION, GENETIC;

EID: 84887323616     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-06-508028     Document Type: Article

References (37)

1. Nogai H, Dörken B, Lenz G. Pathogenesis of non-Hodgkin’s lymphoma. J Clin Oncol. 2011;29(14): 1803-1811.
2. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-511.
3. Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells. J Exp Med. 2001; 194(12):1861-1874.
4. Compagno M, Lim WK, Grunn A, et al. Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. Nature. 2009; 459(7247):717-721.
5. Ghosh S, Hayden MS. Celebrating 25 years of NF-kB research. Immunol Rev. 2012;246(1):5-13.
6. Hinz M, Arslan SC, Scheidereit C. It takes two to tango: IkBs, the multifunctional partners of NF-kB. Immunol Rev. 2012;246(1):59-76.
7. Staudt LM. Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol. 2010;2(6): a000109.
8. Jost PJ, Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood. 2007;109(7): 2700-2707.
9. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol. 2004;25(6):280-288.
10. Lenz G, Davis RE, Ngo VN, et al. Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. Science. 2008;319(5870):1676-1679.
11. Davis RE, Ngo VN, Lenz G, et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. Nature. 2010;463(7277):88-92.
12. Ngo VN, Young RM, Schmitz R, et al. Oncogenically active MYD88 mutations in human lymphoma. Nature. 2011;470(7332):115-119.
13. Kato M, Sanada M, Kato I, et al. Frequent inactivation of A20 in B-cell lymphomas. Nature. 2009;459(7247):712-716.
14. Yamazaki S, Muta T, Takeshige K. A novel IkappaB protein, IkappaB-zeta, induced by proinflammatory stimuli, negatively regulates nuclear factor-kappaB in the nuclei. J Biol Chem. 2001;276(29):27657-27662.
15. Kitamura H, Kanehira K, Okita K, Morimatsu M, Saito M. MAIL, a novel nuclear I kappa B protein that potentiates LPS-induced IL-6 production. FEBS Lett. 2000;485(1):53-56.
16. Haruta H, Kato A, Todokoro K. Isolation of a novel interleukin-1-inducible nuclear protein bearing ankyrin-repeat motifs. J Biol Chem. 2001;276(16): 12485-12488.
17. Muta T. IkappaB-zeta: an inducible regulator of nuclear factor-kappaB. Vitam Horm. 2006;74: 301-316.
18. Eto A, Muta T, Yamazaki S, Takeshige K. Essential roles for NF-kappa B and a Toll/IL-1 receptor domain-specific signal(s) in the induction of I kappa B-zeta. Biochem Biophys Res Commun. 2003;301(2):495-501.
19. Yamamoto M, Yamazaki S, Uematsu S, et al. Regulation of Toll/IL-1-receptor-mediated gene expression by the inducible nuclear protein IkappaBzeta. Nature. 2004;430(6996):218-222.
20. Lenz G, Wright GW, Emre NC, et al. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc Natl Acad Sci USA. 2008;105(36):13520-13525.
21. Wenzel SS, Grau M, Mavis C, et al. MCL1 is deregulated in subgroups of diffuse large B-cell lymphoma. Leukemia. 2013;27(6):1381-1390.
22. Lenz G, Wright G, Dave SS, et al; Lymphoma/ Leukemia Molecular Profiling Project. Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008;359(22):2313-2323.
23. Dave SS, Fu K, Wright GW, et al; Lymphoma/ Leukemia Molecular Profiling Project. Molecular diagnosis of Burkitt’s lymphoma. N Engl J Med. 2006;354(23):2431-2442.
24. Shaughnessy JD Jr, Zhan F, Burington BE, et al. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109(6):2276-2284.
25. Tiacci E, Döring C, Brune V, et al. Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma. Blood. 2012; 120(23):4609-4620.
26. Pasqualucci L, Trifonov V, Fabbri G, et al. Analysis of the coding genome of diffuse large B-cell lymphoma. Nat Genet. 2011;43(9):830-837.
27. Morin RD, Mendez-Lago M, Mungall AJ, et al. Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 2011;476(7360): 298-303.
28. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373-384.
29. Shaffer AL, Wright G, Yang L, et al. A library of gene expression signatures to illuminate normal and pathological lymphoid biology. Immunol Rev. 2006;210:67-85.
30. Hailfinger S, Lenz G, Ngo V, et al. Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma. Proc Natl Acad Sci USA. 2009;106(47):19946-19951.
31. Trinh DV, Zhu N, Farhang G, Kim BJ, Huxford T. The nuclear I kappaB protein I kappaB zeta specifically binds NF-kappaB p50 homodimers and forms a ternary complex on kappaB DNA. J Mol Biol. 2008;379(1):122-135.
32. Totzke G, Essmann F, Pohlmann S, Lindenblatt C, Jänicke RU, Schulze-Osthoff K. A novel member of the IkappaB family, human IkappaBzeta, inhibits transactivation of p65 and its DNA binding. J Biol Chem. 2006;281(18):12645-12654.
33. Hailfinger S, Nogai H, Pelzer C, et al. Malt1-dependent RelB cleavage promotes canonical NF-kappaB activation in lymphocytes and lymphoma cell lines. Proc Natl Acad Sci USA. 2011;108(35):14596-14601.
34. Yamazaki S, Muta T, Matsuo S, Takeshige K. Stimulus-specific induction of a novel nuclear factor-kappaB regulator, IkappaB-zeta, via Toll/ Interleukin-1 receptor is mediated by mRNA stabilization. J Biol Chem. 2005;280(2): 1678-1687.
35. Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell. 2007;12(2):115-130.
36. Bargou RC, Emmerich F, Krappmann D, et al. Constitutive nuclear factor-kappaB-RelA activation is required for proliferation and survival of Hodgkin’s disease tumor cells. J Clin Invest. 1997;100(12):2961-2969.
37. Keats JJ, Fonseca R, Chesi M, et al. Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. Cancer Cell. 2007; 12(2):131-144.